Skip to content

A multicenter randomized controlled clinical study comparing the safety and efficacy of vitrectomy combined with subretinal injection of alteplase and intravitreal injection of alteplase combined with pneumatic displacement in the treatment of massive macular subretinal hemorrhage caused by age-related macular degeneration

A multicenter randomized controlled clinical study comparing the safety and efficacy of vitrectomy combined with subretinal injection of alteplase and intravitreal injection of alteplase combined with pneumatic displacement in the treatment of massive macular subretinal hemorrhage caused by age-related macular degeneration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099976
Enrollment
Unknown
Registered
2025-04-01
Start date
2025-04-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Massive macular subretinal hemorrhage caused by age-related macular degeneration

Interventions

Vitrectomy combined with subretinal injection of alteplase group:Vitrectomy combined with subretinal injection of alteplase
Vitreous cavity injection of alteplase combined with pneumatic displacement surgery group:Vitreous cavity injection of alteplase combined with pneumatic displacement surgery

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Subretinal hemorrhage caused by AMD; 2. subretinal hemorrhage involving the macula and>2PD; 3. blood mainly located on the RPE, macular OCT thickness >= 250um; 4. subretinal hemorrhage <= 15 days; 5. age over 40 years old, and good compliance with study follow-up.

Exclusion criteria

Exclusion criteria: 1. Major macular subretinal hemorrhage caused by other reasons; 2. subretinal hemorrhage not involving the macula; 3. subretinal hemorrhage greater than 15 days; 4. patients with vitreous hemorrhage; 5. severe macular and optic nerve disease; 6. macular OCT thickness<250um.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;

Secondary

MeasureTime frame
Bleeding area;visual field;macular thickness;spontaneous fluorescence;

Countries

China

Contacts

Public ContactYuhong Cheng

The First Affiliated Hospital of Xi'an Jiaotong University

oculistcyh@163.com+86 29 85323960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026